LONDON – The Advanced Research and Invention Agency (Aria) has allocated £50 million in taxpayer funds to 14 US-based technology firms and venture capital groups, sparking scrutiny over the agency’s mandate to bolster domestic innovation.
The expenditure highlights a strategic tension within the UK’s effort to secure a position as a scientific superpower, as a significant portion of high-risk R&D capital is flowing to established US innovation hubs rather than domestic regional projects.
Modeled after the US DARPA agency, Aria was established to fund high-risk, high-reward “moonshot” projects. However, transparency disclosures reveal that more than one-eighth of the agency’s £400 million in research and development funding over the past two years has been directed toward US entities.
The allocation of funds is distributed as follows:
- US Tech Firms: £23 million distributed across nine companies.
- Normal Computing: £6 million (a US firm that established a UK presence weeks before receiving the grant).
- US Venture Capital Groups: £29.4 million distributed across three groups.
Among the recipients is Rain Neuromorphics, a company backed by OpenAI CEO Sam Altman. The firm, which focuses on neuromorphic computing to challenge traditional AI chip architectures, was reported to be near collapse shortly after receiving Aria funding. While two founders have since left the company, it continues to deliver a project for the agency.
Venture Capital and Ecosystem Integration
Aria was created by the government as a deliberately light-touch, high-autonomy counterpart to traditional research councils, with ministers arguing that placing bold bets on unproven technologies would help crowd in private capital and anchor cutting-edge firms in the UK. The latest awards, however, have sharpened questions in Westminster about who ultimately benefits from that risk.
A substantial portion of the funding has targeted US venture capital firms tasked with identifying UK tech talent and building pipelines of commercially ready start-ups. This includes Pillar VC, which received a £10.9 million contract one day after incorporating in the UK, prompting concerns from MPs and civil society groups over due diligence, value for money, and whether the government is outsourcing core innovation policy to foreign investors.
Renaissance Philanthropy, an organization backed by former Google CEO Eric Schmidt, received £13.3 million. The group stated it is working with governments in the UK, Germany, Japan, and the US to build R&D ecosystems, positioning itself as a convenor between public research agencies and frontier-technology companies.
Other US-based service providers receiving funds include:
- Fifty Years: Received £7 million to conduct a 14-week course for 50 students, teaching scientists how to launch companies.
- CIC Venture Cafe Global Institute: Received £5.4 million to operate “venture cafes” across the UK.
Officials argue these partnerships are intended to plug UK researchers into global networks of capital and expertise, in line with the UK’s National AI Strategy goal of attracting world-leading talent and investment. Critics counter that the financial flow risks reinforcing the gravitational pull of existing US monopolies and could see taxpayer-funded breakthroughs ultimately controlled or scaled from abroad.
“Disguised as promoting moonshot projects, the government is using taxpayer money to further expand the power of the US tech ecosystem,” said Cecilia Rikap, an economics professor at University College London. “This is not a surprise coming from a government that has agreed to be not only Trump’s, but also big tech’s, footman.”
Governance and Intellectual Property
Aria operates under bespoke legislation, the Advanced Research and Invention Agency Act 2022, which mandates that the organization benefit the UK by driving economic growth, supporting scientific innovation, or improving the quality of life. The Act grants Aria unusual freedoms compared with other public bodies – including greater flexibility over procurement, staffing and risk appetite – while also exempting it from some conventional transparency requirements.
That design is now under pressure. Chi Onwurah, chair of the Commons science and technology committee, has questioned how funding US-based venture capital firms aligns with Aria’s statutory aims or the government’s repeated commitment to “levelling up” regional innovation outside London and the south-east.
Regional disparities remain a point of contention. Funding distribution is heavily concentrated in London and the south-east; for instance, the West Midlands has received only 0.8% of Aria’s funding, fuelling criticism from local leaders that high-risk innovation finance is bypassing manufacturing-heavy regions that ministers have pledged to support.
Regarding the return on investment, Aria does not typically take shares or intellectual property rights in the companies it funds. Instead, the agency requires a royalty fee to be paid to the UK on any IP commercialized outside the UK. Supporters say this structure is intended to reduce red tape for scientists and entrepreneurs; opponents warn it could leave the public sector with limited leverage if successful companies later redomicile or are acquired by overseas buyers.
Aria has defended its strategy, stating that over 80% of its funding goes to UK-based teams. The agency maintains that international funding is designed to transfer scientific capabilities to the UK through contractual protections, and that US intermediaries can accelerate the creation of globally competitive firms headquartered in Britain.
Some US firms have highlighted their domestic contributions. Normal Computing stated it has reinvested approximately 150% of its award value back into the UK through operations and salaries. MorphoAI reported that over 50% of its employees are now based in the UK, with the majority of operations running from a London office – evidence, they say, that cross-border grants can translate into UK jobs and labs.
Yet the broader accountability framework remains thin. Aria is exempt from freedom of information laws, limiting external scrutiny of individual awards, internal risk assessments and failed projects. The agency also continues to operate without strict public guidelines on the maximum percentage of funding permissible for non-UK businesses, leaving ministers reliant on periodic parliamentary hearings and select committee reviews to reassure voters that a publicly funded “moonshot” agency is not quietly underwriting the next generation of US tech champions.
